Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3
Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3
Wedbush 將表面腫瘤學評級從跑贏大盤下調至中性，將目標價從3美元調整至1.15美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊